- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- fluticasone and salmeterol
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1897–1920
of 4,736
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Long COVID
- Interventions
- WATER+CT, Usual Care
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Asthma, Pulmonary Function, Wheezing, In Utero Nicotine
- Interventions
- No active intervention
- Other
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 6 Months to 4 Years
- Enrollment
- 242 participants
- Timeline
- 2017 – 2024
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • Portland, Oregon
- Conditions
- COVID-19
- Interventions
- Not listed
- Lead sponsor
- Huntington Memorial Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Pasadena, California
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chemotherapy-Related Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Hodgkin Lymphoma, Langerhans Cell Histiocytosis, Minimal Residual Disease, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Myelodysplastic Syndrome, Small Lymphocytic Lymphoma, Therapy-Related Myelodysplastic Syndrome
- Interventions
- Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide, Filgrastim-sndz, Fludarabine, Melphalan, Mycophenolate Mofetil, Rituximab, Tacrolimus, Total-Body Irradiation, Umbilical Cord Blood Transplantation
- Biological · Drug · Radiation + 1 more
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Vaping, Complication of Anesthesia
- Interventions
- Not listed
- Lead sponsor
- Navy Medical Center San Diego
- Federal
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 300 participants
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Pamrevlumab, Placebo
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 393 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
- Conditions
- Obesity, Respiratory Insufficiency
- Interventions
- Not listed
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Not listed
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 5
- States / cities
- Evanston, Illinois • Chapel Hill, North Carolina • Durham, North Carolina + 1 more
- Conditions
- Chronic Obstructive Pulmonary Disease, Emphysema, Chronic Bronchitis With Airway Obstruction
- Interventions
- Quercetin 1000 mg, Quercetin 500 MG, Placebo
- Drug
- Lead sponsor
- Temple University
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Moderate to Severe Chronic Obstructive Pulmonary Disease
- Interventions
- PF-07275315 dose 1, PF-07275315-dose 2, Placebo, PF-07275315-dose 3
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 1,156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 50 more
- Conditions
- COPD, Chronic Bronchitis
- Interventions
- Losartan 50 mg, Losartan 100 mg
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Covid19
- Interventions
- Hyperbaric oxygen therapy
- Combination Product
- Lead sponsor
- Peter Lindholm
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Fibrosis Lung
- Interventions
- FAPI tracer, PET/MRI
- Drug · Device
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Asthma
- Interventions
- QAW039, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 894 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 55
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Litchfield Park, Arizona + 49 more
- Conditions
- Brain Injury Traumatic Severe (Diagnosis), Coma, Consciousness, Level Altered, Anoxic Brain Injury
- Interventions
- Methylphenidate
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Idiopathic Pulmonary Fibrosis, Emphysema or COPD
- Interventions
- CD3/CD19 negative hematopoietic stem cells, Rituximab, Alemtuzumab, Fludarabine, Thiotepa, G-CSF, Hydroxyurea
- Biological · Drug
- Lead sponsor
- Paul Szabolcs
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Sodium Nitrite Inhalation Solution, Placebo and AIR001 Inhalation Solution (Expansion arm)
- Drug
- Lead sponsor
- Aires Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Non Small Cell Lung Cancer, Lung Cancer Stage 1
- Interventions
- Liposomal Bupivacaine, Bupivacaine-Epinephrine
- Drug
- Lead sponsor
- Southern Illinois University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Springfield, Illinois
- Conditions
- AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma, HIV Infection, Kaposi Sarcoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Malignant Neoplasm, Refractory Classic Hodgkin Lymphoma, Refractory Malignant Neoplasm, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Melanoma
- Interventions
- Antiretroviral Therapy, Biopsy, Biospecimen Collection, Computed Tomography, Pembrolizumab, Positron Emission Tomography
- Drug · Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more
- Conditions
- COPD
- Interventions
- QBM076, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Cystic Fibrosis in Children, Cystic Fibrosis, Chronic Rhinosinusitis (Diagnosis), Olfactory Disorder, Olfactory Impairment
- Interventions
- Ivacaftor or elexacaftor/tezacaftor/ivacaftor
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 2 Years to 8 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Iowa City, Iowa • Kansas City, Kansas + 3 more
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm, Hormone Receptor Positive Breast Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Triple-Negative Breast Carcinoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Bintrafusp Alfa, Pimasertib, Quality-of-Life Assessment
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- MEDI4736
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 446 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 28
- States / cities
- Goodyear, Arizona • Santa Rosa, California • New Haven, Connecticut + 22 more